MET and non-small cell lung carcinoma: Despite this promising result, however, the same combined approach of EGFR-TKI+cMET inhibitors failed when used in clinical trials involving human patients with EGFR-mutated NSCLC.22 This setback has prompted the search for a dual inhibitor that could target both EGFR and cMET simultaneously, as this might show greater effectiveness than the combination of TKI+cMET inhibitors against EGFR-TKI-resistant NSCLC.